MedPageToday -- Cancer patients treated with the angiogenesis inhibitor bevacizumab (Avastin) had almost 50% more fatal adverse events compared with control groups, data from a meta-analysis of 10,000 patients showed. The 16 studies included in the analysis had a 2.5% cumulative incidence of fatal events in bevacizumab-treated patients compared with 1.7% among patients treated with regimens that did not include the targeted agent.